CO5690608A2 - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica - Google Patents

4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Info

Publication number
CO5690608A2
CO5690608A2 CO06051033A CO06051033A CO5690608A2 CO 5690608 A2 CO5690608 A2 CO 5690608A2 CO 06051033 A CO06051033 A CO 06051033A CO 06051033 A CO06051033 A CO 06051033A CO 5690608 A2 CO5690608 A2 CO 5690608A2
Authority
CO
Colombia
Prior art keywords
ome
quinolincarbonitrilos
mielogen
anilino
leukemia
Prior art date
Application number
CO06051033A
Other languages
English (en)
Spanish (es)
Inventor
Frank Charles Boschelli
Jennifer Michele Golas
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5690608(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5690608A2 publication Critical patent/CO5690608A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO06051033A 2003-11-06 2006-05-26 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica CO5690608A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
CO5690608A2 true CO5690608A2 (es) 2006-10-31

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06051033A CO5690608A2 (es) 2003-11-06 2006-05-26 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica

Country Status (18)

Country Link
US (2) US7417148B2 (https=)
EP (1) EP1680119A1 (https=)
JP (1) JP2007533655A (https=)
KR (1) KR20060118461A (https=)
CN (1) CN1874776A (https=)
AU (1) AU2004289243B2 (https=)
BR (1) BRPI0416289A (https=)
CA (1) CA2543163A1 (https=)
CO (1) CO5690608A2 (https=)
CR (1) CR8350A (https=)
EC (1) ECSP066548A (https=)
IL (1) IL175424A0 (https=)
MX (1) MXPA06004744A (https=)
NO (1) NO20062255L (https=)
RU (1) RU2006113691A (https=)
SG (1) SG146681A1 (https=)
WO (1) WO2005046693A1 (https=)
ZA (1) ZA200603596B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CN103705517A (zh) 2005-06-17 2014-04-09 得克萨斯大学体系董事会 Src激酶抑制剂对溶骨性病变的抑制
CN101252931A (zh) * 2005-06-24 2008-08-27 惠氏公司 用于治疗癌症的4-苯胺基-3-喹啉甲腈
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2964162C (en) * 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
US7919625B2 (en) 2011-04-05
NO20062255L (no) 2006-08-01
IL175424A0 (en) 2008-04-13
US20050101780A1 (en) 2005-05-12
BRPI0416289A (pt) 2007-01-23
US7417148B2 (en) 2008-08-26
SG146681A1 (en) 2008-10-30
MXPA06004744A (es) 2006-07-05
CA2543163A1 (en) 2005-05-26
EP1680119A1 (en) 2006-07-19
CN1874776A (zh) 2006-12-06
CR8350A (es) 2006-10-06
US20100029677A1 (en) 2010-02-04
RU2006113691A (ru) 2007-12-20
ZA200603596B (en) 2009-12-30
AU2004289243A1 (en) 2005-05-26
AU2004289243B2 (en) 2010-07-22
KR20060118461A (ko) 2006-11-23
JP2007533655A (ja) 2007-11-22
WO2005046693A1 (en) 2005-05-26
ECSP066548A (es) 2006-10-17

Similar Documents

Publication Publication Date Title
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
CO6160236A2 (es) Inhibidor de quinasa
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
AR077415A2 (es) Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos
AR039698A1 (es) Agonistas de los receptores cannabinoides
ES2543607T3 (es) Ciertas amidas sustituidas, método de obtención, y método de su uso
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
TW200641539A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
UY28014A1 (es) Compuestos quimicos
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
WO2007099162A3 (fr) Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques
TW200728915A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
CO5700776A2 (es) Compuestos utiles para el tratamiento de enfermedades
PA8531701A1 (es) Derivados de pirimidina
UY27979A1 (es) Indoles sustituidos en posición 2,4
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
UY27610A1 (es) Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos
AR044175A1 (es) Compuestos de cefemo
AR035601A1 (es) Procesos de preparacion de inhibidores del intercambiador de sodio-hidrogeno de tipo 1, inhibidores, sales de dichos compuestos, composiciones farmaceuticas y uso de los mismos en la preparación de medicamentos
CO5170535A1 (es) Derivados de n-[2-(4-aminofenil)etil]2,3-dihidro-1,4- benzodioxin-2-metanamina, su preparacion y su aplciacion en terapeutica
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR048582A1 (es) Metodos para tratar esclerosis multiple y composiciones farmaceuticas para ese fin
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende

Legal Events

Date Code Title Description
FC Application refused